Q1 EPS Estimate for Bicycle Therapeutics Boosted by Analyst

Bicycle Therapeutics plc (NASDAQ:BCYC) – Analysts at HC Wainwright upped their Q1 2025 EPS estimates for Bicycle Therapeutics in a research note issued on Monday, December 16th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.93) for the quarter, up from their prior forecast of ($0.99). HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Bicycle Therapeutics’ Q2 2025 earnings at ($0.96) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.93) EPS, FY2025 earnings at ($3.82) EPS, FY2026 earnings at ($4.14) EPS, FY2027 earnings at ($3.49) EPS and FY2028 earnings at ($2.12) EPS.

A number of other analysts have also recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Royal Bank of Canada restated an “outperform” rating and issued a $35.00 price target on shares of Bicycle Therapeutics in a research note on Friday, November 1st. JMP Securities reduced their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Finally, Stephens started coverage on Bicycle Therapeutics in a research note on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price on the stock. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.25.

Bicycle Therapeutics Stock Performance

BCYC stock opened at $15.00 on Thursday. Bicycle Therapeutics has a 1 year low of $12.17 and a 1 year high of $28.67. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -4.56 and a beta of 0.86. The stock’s fifty day moving average is $22.27 and its two-hundred day moving average is $22.61.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. During the same quarter in the previous year, the firm posted ($1.26) EPS. The business’s revenue for the quarter was down 50.0% compared to the same quarter last year.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 6,256 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the completion of the sale, the chief accounting officer now owns 19,241 shares in the company, valued at $483,141.51. This represents a 24.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin Lee sold 3,212 shares of Bicycle Therapeutics stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total transaction of $71,499.12. Following the sale, the chief executive officer now directly owns 380,864 shares of the company’s stock, valued at $8,478,032.64. This trade represents a 0.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,840 shares of company stock valued at $259,128 over the last quarter. Company insiders own 8.50% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Assetmark Inc. bought a new position in Bicycle Therapeutics during the third quarter valued at approximately $34,000. GAMMA Investing LLC raised its holdings in shares of Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after purchasing an additional 1,038 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Bicycle Therapeutics by 69.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after purchasing an additional 2,918 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Bicycle Therapeutics in the 2nd quarter valued at $206,000. Finally, Crossmark Global Holdings Inc. bought a new stake in Bicycle Therapeutics in the third quarter worth $257,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.